J-l J. Lee
Seoul, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: Five-year results from the phase III KEYNOTE-564 study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 29, 2026
Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 07, 2025
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 14, 2023
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 27, 2022
ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups.
Journal: ESMO open
Published: November 20, 2020
Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10-17).
Journal: British journal of cancer
Published: August 04, 2014
Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed.
Journal: British journal of cancer
Published: January 13, 2014
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: December 21, 2013
Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients.
Journal: British journal of cancer
Published: November 17, 2013
First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC.
Journal: British journal of cancer
Published: October 15, 2013
p34 is a novel regulator of the oncogenic behavior of NEDD4-1 and PTEN.
Journal: Cell death and differentiation
Published: March 05, 2013
Last Updated: 09/26/2026